Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain

Mark Palangio, Donald W Northfelt, Russell K. Portenoy, Daniel Brookoff, Ralph T. Doyle, Bruce E. Dornseif, Michael C. Damask

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The objective of this open-label, repeated-dose, single-treatment, multicenter study was to evaluate the outcomes associated with a standardized conversion from prior opioid therapy to a novel, once-daily, OROS® osmotic technology, extended-release (ER) hydromorphone formulation in an outpatient population with chronic malignant or nonmalignant pain. The study period was divided into 3 phases: the prior opioid stabilization phase (≥3 days), the conversion and titration phase (3-21 days), and the maintenance phase (14 days). Patients were evaluated at 5 visits during the study period. Analgesic efficacy was measured using the Brief Pain Inventory (BPI). At baseline, patients were required to have daily oral morphine equivalent requirements of ≥45 mg. Prior oral or transdermal opioid therapy was converted to single daily doses of ER hydromorphone (8, 16, 32, and 64 mg tablets) at a 5:1 (morphine equivalent to hydromorphone) ratio. Immediate-release (IR) hydromorphone was given as rescue medication for breakthrough pain. Among the 445 patients who enrolled, 404 received the study medication. Of these, 73 (18.1%) had chronic malignant pain and 331 (81.9%) had chronic nonmalignant pain. Dose stabilization (defined as a 3-day period during which the total daily dose of ER hydromorphone remained unchanged and ≤3 doses of IR hydromorphone per day were required) was attained by 73.8% of patients (298/404), of whom 70.1% (209/298) were stabilized with ≤2 titration steps. The mean ± standard deviation (SD) time to dose stabilization was 12.1 ± 5.7 days (range of 3 to 33 days). The mean ± SD final daily dose of ER hydromorphone was 63.4 ± 129.2 mg. The mean ± SD final daily dose of IR hydromorphone was 11.5 ± 36.4 mg, and the mean ± SD final number of daily doses of IR hydromorphone was 1.7 ± 1.3. Intent-to-treat and completer analysis demonstrated significant improvements in BPI ratings from prior opioid therapy to the end of ER hydromorphone therapy (P < 0.01 for all pairwise comparisons). Adverse events were consistent with those expected of an opioid agonist in such a patient group, affecting primarily the gastrointestinal and central nervous systems. This uncontrolled study delineates a regimen by which patients with chronic malignant or nonmalignant pain can be readily converted from prior opioid therapy and titrated to an appropriate maintenance dose of ER hydromorphone. Controlled longitudinal studies are required to further evaluate the use of ER hydromorphone in patients with discrete chronic malignant or nonmalignant pain conditions.

Original languageEnglish (US)
Pages (from-to)355-368
Number of pages14
JournalJournal of Pain and Symptom Management
Volume23
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Hydromorphone
Technology
Pain
Opioid Analgesics
Therapeutics
Chronic Pain
Morphine
Breakthrough Pain
Equipment and Supplies
Tablets
Multicenter Studies
Longitudinal Studies
Analgesics

Keywords

  • Chronic malignant pain
  • Chronic nonmalignant pain
  • Dose conversion
  • Extended-release
  • Hydromorphone
  • Titration

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. / Palangio, Mark; Northfelt, Donald W; Portenoy, Russell K.; Brookoff, Daniel; Doyle, Ralph T.; Dornseif, Bruce E.; Damask, Michael C.

In: Journal of Pain and Symptom Management, Vol. 23, No. 5, 2002, p. 355-368.

Research output: Contribution to journalArticle

@article{6209777d95864a0facd0f0de369653c7,
title = "Dose conversion and titration with a novel, once-daily, OROS{\circledR} osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain",
abstract = "The objective of this open-label, repeated-dose, single-treatment, multicenter study was to evaluate the outcomes associated with a standardized conversion from prior opioid therapy to a novel, once-daily, OROS{\circledR} osmotic technology, extended-release (ER) hydromorphone formulation in an outpatient population with chronic malignant or nonmalignant pain. The study period was divided into 3 phases: the prior opioid stabilization phase (≥3 days), the conversion and titration phase (3-21 days), and the maintenance phase (14 days). Patients were evaluated at 5 visits during the study period. Analgesic efficacy was measured using the Brief Pain Inventory (BPI). At baseline, patients were required to have daily oral morphine equivalent requirements of ≥45 mg. Prior oral or transdermal opioid therapy was converted to single daily doses of ER hydromorphone (8, 16, 32, and 64 mg tablets) at a 5:1 (morphine equivalent to hydromorphone) ratio. Immediate-release (IR) hydromorphone was given as rescue medication for breakthrough pain. Among the 445 patients who enrolled, 404 received the study medication. Of these, 73 (18.1{\%}) had chronic malignant pain and 331 (81.9{\%}) had chronic nonmalignant pain. Dose stabilization (defined as a 3-day period during which the total daily dose of ER hydromorphone remained unchanged and ≤3 doses of IR hydromorphone per day were required) was attained by 73.8{\%} of patients (298/404), of whom 70.1{\%} (209/298) were stabilized with ≤2 titration steps. The mean ± standard deviation (SD) time to dose stabilization was 12.1 ± 5.7 days (range of 3 to 33 days). The mean ± SD final daily dose of ER hydromorphone was 63.4 ± 129.2 mg. The mean ± SD final daily dose of IR hydromorphone was 11.5 ± 36.4 mg, and the mean ± SD final number of daily doses of IR hydromorphone was 1.7 ± 1.3. Intent-to-treat and completer analysis demonstrated significant improvements in BPI ratings from prior opioid therapy to the end of ER hydromorphone therapy (P < 0.01 for all pairwise comparisons). Adverse events were consistent with those expected of an opioid agonist in such a patient group, affecting primarily the gastrointestinal and central nervous systems. This uncontrolled study delineates a regimen by which patients with chronic malignant or nonmalignant pain can be readily converted from prior opioid therapy and titrated to an appropriate maintenance dose of ER hydromorphone. Controlled longitudinal studies are required to further evaluate the use of ER hydromorphone in patients with discrete chronic malignant or nonmalignant pain conditions.",
keywords = "Chronic malignant pain, Chronic nonmalignant pain, Dose conversion, Extended-release, Hydromorphone, Titration",
author = "Mark Palangio and Northfelt, {Donald W} and Portenoy, {Russell K.} and Daniel Brookoff and Doyle, {Ralph T.} and Dornseif, {Bruce E.} and Damask, {Michael C.}",
year = "2002",
doi = "10.1016/S0885-3924(02)00390-1",
language = "English (US)",
volume = "23",
pages = "355--368",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain

AU - Palangio, Mark

AU - Northfelt, Donald W

AU - Portenoy, Russell K.

AU - Brookoff, Daniel

AU - Doyle, Ralph T.

AU - Dornseif, Bruce E.

AU - Damask, Michael C.

PY - 2002

Y1 - 2002

N2 - The objective of this open-label, repeated-dose, single-treatment, multicenter study was to evaluate the outcomes associated with a standardized conversion from prior opioid therapy to a novel, once-daily, OROS® osmotic technology, extended-release (ER) hydromorphone formulation in an outpatient population with chronic malignant or nonmalignant pain. The study period was divided into 3 phases: the prior opioid stabilization phase (≥3 days), the conversion and titration phase (3-21 days), and the maintenance phase (14 days). Patients were evaluated at 5 visits during the study period. Analgesic efficacy was measured using the Brief Pain Inventory (BPI). At baseline, patients were required to have daily oral morphine equivalent requirements of ≥45 mg. Prior oral or transdermal opioid therapy was converted to single daily doses of ER hydromorphone (8, 16, 32, and 64 mg tablets) at a 5:1 (morphine equivalent to hydromorphone) ratio. Immediate-release (IR) hydromorphone was given as rescue medication for breakthrough pain. Among the 445 patients who enrolled, 404 received the study medication. Of these, 73 (18.1%) had chronic malignant pain and 331 (81.9%) had chronic nonmalignant pain. Dose stabilization (defined as a 3-day period during which the total daily dose of ER hydromorphone remained unchanged and ≤3 doses of IR hydromorphone per day were required) was attained by 73.8% of patients (298/404), of whom 70.1% (209/298) were stabilized with ≤2 titration steps. The mean ± standard deviation (SD) time to dose stabilization was 12.1 ± 5.7 days (range of 3 to 33 days). The mean ± SD final daily dose of ER hydromorphone was 63.4 ± 129.2 mg. The mean ± SD final daily dose of IR hydromorphone was 11.5 ± 36.4 mg, and the mean ± SD final number of daily doses of IR hydromorphone was 1.7 ± 1.3. Intent-to-treat and completer analysis demonstrated significant improvements in BPI ratings from prior opioid therapy to the end of ER hydromorphone therapy (P < 0.01 for all pairwise comparisons). Adverse events were consistent with those expected of an opioid agonist in such a patient group, affecting primarily the gastrointestinal and central nervous systems. This uncontrolled study delineates a regimen by which patients with chronic malignant or nonmalignant pain can be readily converted from prior opioid therapy and titrated to an appropriate maintenance dose of ER hydromorphone. Controlled longitudinal studies are required to further evaluate the use of ER hydromorphone in patients with discrete chronic malignant or nonmalignant pain conditions.

AB - The objective of this open-label, repeated-dose, single-treatment, multicenter study was to evaluate the outcomes associated with a standardized conversion from prior opioid therapy to a novel, once-daily, OROS® osmotic technology, extended-release (ER) hydromorphone formulation in an outpatient population with chronic malignant or nonmalignant pain. The study period was divided into 3 phases: the prior opioid stabilization phase (≥3 days), the conversion and titration phase (3-21 days), and the maintenance phase (14 days). Patients were evaluated at 5 visits during the study period. Analgesic efficacy was measured using the Brief Pain Inventory (BPI). At baseline, patients were required to have daily oral morphine equivalent requirements of ≥45 mg. Prior oral or transdermal opioid therapy was converted to single daily doses of ER hydromorphone (8, 16, 32, and 64 mg tablets) at a 5:1 (morphine equivalent to hydromorphone) ratio. Immediate-release (IR) hydromorphone was given as rescue medication for breakthrough pain. Among the 445 patients who enrolled, 404 received the study medication. Of these, 73 (18.1%) had chronic malignant pain and 331 (81.9%) had chronic nonmalignant pain. Dose stabilization (defined as a 3-day period during which the total daily dose of ER hydromorphone remained unchanged and ≤3 doses of IR hydromorphone per day were required) was attained by 73.8% of patients (298/404), of whom 70.1% (209/298) were stabilized with ≤2 titration steps. The mean ± standard deviation (SD) time to dose stabilization was 12.1 ± 5.7 days (range of 3 to 33 days). The mean ± SD final daily dose of ER hydromorphone was 63.4 ± 129.2 mg. The mean ± SD final daily dose of IR hydromorphone was 11.5 ± 36.4 mg, and the mean ± SD final number of daily doses of IR hydromorphone was 1.7 ± 1.3. Intent-to-treat and completer analysis demonstrated significant improvements in BPI ratings from prior opioid therapy to the end of ER hydromorphone therapy (P < 0.01 for all pairwise comparisons). Adverse events were consistent with those expected of an opioid agonist in such a patient group, affecting primarily the gastrointestinal and central nervous systems. This uncontrolled study delineates a regimen by which patients with chronic malignant or nonmalignant pain can be readily converted from prior opioid therapy and titrated to an appropriate maintenance dose of ER hydromorphone. Controlled longitudinal studies are required to further evaluate the use of ER hydromorphone in patients with discrete chronic malignant or nonmalignant pain conditions.

KW - Chronic malignant pain

KW - Chronic nonmalignant pain

KW - Dose conversion

KW - Extended-release

KW - Hydromorphone

KW - Titration

UR - http://www.scopus.com/inward/record.url?scp=0036242279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036242279&partnerID=8YFLogxK

U2 - 10.1016/S0885-3924(02)00390-1

DO - 10.1016/S0885-3924(02)00390-1

M3 - Article

C2 - 12007754

AN - SCOPUS:0036242279

VL - 23

SP - 355

EP - 368

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 5

ER -